To further investigate whether the JAK inhibitor ruxolitinib alleviates hyperuricemia-induced mitochondrial dysfunction and oxidative stress by regulating HMGCS2 expression, we conducted experiments in which ruxolitinib was used to treat uric acid-induced normal cells and HMGCS2 stably overexpressing AC-16 cells. Here, HMGCS2 is linked to hyperuricemia.